Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents

American Heart Journal

Volumn 154, Issue 4, 2007, Pages 695-701

  Feldman, Dmitriy N ^a   Wong, S Chiu ^a   Gade, Christopher L ^a   Gidseg, David S ^a   Bergman, Geoffrey ^a   Minutello, Robert M ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN; TIROFIBAN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIAC PATIENT; CAUSE OF DEATH; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; DEATH; DISEASE COURSE; DRUG ELUTING STENT; DRUG FATALITY; DRUG USE; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMODYNAMICS; HUMAN; INCIDENCE; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; SCORING SYSTEM; SHOCK; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; STROKE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ANTITHROMBINS; CORONARY DISEASE; CREATINE KINASE, MB FORM; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HIRUDINS; HUMANS; INTRAOPERATIVE COMPLICATIONS; LOGISTIC MODELS; MALE; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME; TROPONIN I;

EID: 34548801993     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.023     Document Type: Article

References (26)

1. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352 (1998) 87-92
2. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
3. Bittl J.A., Strony J., Brinker J.A., et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 333 (1995) 764-769
4. Bittl J.A., Chaitman B.R., Feit F., et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142 (2001) 952-959
5. Shammas N.W. Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev 23 (2005) 345-360
6. Lincoff A.M., Bittl J.A., Kleiman N.S., et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93 (2004) 1092-1096
7. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
8. Ebrahimi R., Lincoff A.M., Bittl J.A., et al. Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis. J Cardiovasc Pharmacol Ther 10 (2005) 209-216
9. Gurm H.S., Rajagopal V., Fathi R., et al. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol 95 (2005) 716-721
10. Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292 (2004) 696-703
11. Stone G.W., White H.D., Ohman E.M., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
12. Dangas G., Lasic Z., Mehran R., et al. Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study). Am J Cardiol 96 (2005) 659-663
13. Rha S.W., Kuchulankanti P.K., Pakala R., et al. Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. Am J Cardiol 94 (2004) 1047-1050
14. Chieffo A., Melzi G., Rogacka R., et al. Safety and feasibility of bivalirudin with either Cypher or TAXUS drug-eluting stent during percutaneous coronary intervention. Eurointervention 1 (2005) 70-74
15. Mishkel G.J., Moore A.L., Markwell S.J., et al. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results. J Invasive Cardiol 19 (2007) 63-68
16. Sesso H.D., Paffenbarger R.S., and Lee I.M. Comparison of National Death Index and World Wide Web death searches. Am J Epidemiol 152 (2000) 107-111
17. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
18. Lefkovits J., and Topol E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation 90 (1994) 1522-1536
19. Parry M.A., Maraganore J.M., and Stone S.R. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 33 (1994) 14807-14814
20. Kinnaird T.D., Stabile E., Mintz G.S., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
21. Stone G.W., McLaurin B.T., Cox D.A., et al., for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
22. Stone G.W., Bertrand M.E., Lincoff A.M., et al. A prospective, randomized trial of bivalirudin in acute coronary syndromes: one year results from the ACUITY trial. J Am Coll Cardiol 49 Suppl B (2007) 10B
23. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98 (1998) 2695-2701
24. Coller B.S. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 78 (1997) 730-735
25. Topol E.J., Lincoff A.M., Kereiakes D.J., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 113 (2002) 1-6
26. Saw J., Lincoff A.M., DeSmet W., et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. J Am Coll Cardiol 44 (2004) 1194-1199